Taiho vs. Aurobindo: Oncology Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd. et al. |
| Case Number | 1:22-cv-01611 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Dec 20, 2022 – Apr 3, 2024 470 days |
| Outcome | Dismissed with Prejudice (Settlement) |
| Patents at Issue | |
| Accused Products | Method for treating cancer patients with severe renal impairment |
Case Overview
The Parties
⚖️ Plaintiff
Japan-based oncology-focused pharmaceutical company with a robust portfolio of cancer therapies, including products for patients with severe renal impairment.
🛡️ Defendant
One of the largest global generic pharmaceutical manufacturers, routinely filing ANDAs under the Hatch-Waxman framework.
Patents at Issue
This dispute centered on two U.S. patents claiming methods related to treating cancer patients who present with severe renal impairment. Patent protection in this space carries significant commercial value for pharmaceutical companies.
- • US 10,456,399 B2 — Method for treating cancer patients with severe renal impairment
- • US 10,960,004 B2 — Method for treating cancer patients with severe renal impairment
Developing a new drug or generic?
Check if your formulation or method might infringe these or related patents before clinical trials or ANDA filing.
The Verdict & Legal Analysis
Outcome
On April 3, 2024, after 470 days of litigation, the parties filed a Stipulation of Dismissal With Prejudice pursuant to Federal Rules of Civil Procedure 41(a)(1)(A)(ii) and 41(c). This resolved all claims, counterclaims, and defenses without a judicial ruling on the merits.
Key Legal Issues
The U.S. District Court for the District of Delaware case was a patent infringement action under 35 U.S.C. § 271. The dismissal with prejudice means neither party retains the right to relitigate these specific claims. The retention of jurisdiction clause implies an underlying confidential settlement agreement, likely a licensing arrangement, was reached.
Freedom to Operate (FTO) Analysis in Pharma
This case highlights critical IP risks in oncology drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents in this oncology treatment space
- See which companies are most active in method-of-treatment patents
- Understand claim construction patterns for therapeutic protocols
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug or treatment method.
- Input your drug formulation or treatment protocol details
- AI identifies potentially blocking method-of-treatment patents
- Get actionable risk assessment report for market entry
High Risk Area
Method of treatment for specialty populations
Active Litigation
In oncology method patents
Settlement Trend
Preferred resolution for Hatch-Waxman cases
✅ Key Takeaways
Dismissal with prejudice under FRCP 41(a)(1)(A)(ii) + 41(c) simultaneously extinguishes all counterclaims, providing broader preclusive effect.
Search related case law →Delaware remains the primary venue for Hatch-Waxman patent disputes; retained jurisdiction clauses are essential in pharmaceutical patent settlements.
Explore precedents →Frequently Asked Questions
The case involved U.S. Patent Nos. 10,456,399 B2 and 10,960,004 B2, both covering methods for treating cancer patients with severe renal impairment.
The case was dismissed with prejudice by mutual stipulation under FRCP 41(a)(1)(A)(ii) and 41(c), reflecting a negotiated resolution between the parties. No judicial ruling on infringement or validity was issued.
It reinforces the trend toward pre-trial settlement in Hatch-Waxman cases involving method patents for specialty populations, suggesting these patent types carry sufficient litigation risk to incentivize early resolution.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Federal Case Records — Case 1:22-cv-01611
- USPTO Patent Center — U.S. Patent No. 10,456,399 B2
- USPTO Patent Center — U.S. Patent No. 10,960,004 B2
- Cornell Legal Information Institute — Federal Rules of Civil Procedure 41
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.